Tyrosine peptides, such as L-alanyl-L-tyrosine, have excellent solubility and are potential sources of iv tyrosine. Infusion of Lalanyl-1.-U-'T-tyrosine as part of a total parenteral nutrition reginien in the rat at a level of 0.5 mmole/kg/day resulted in rapid labeling of tissue tyrosine pools, production of I4CO2, incorporation of 14C-labeled tyrosine into protein, and minimal urinary losses (7.7%). Plasnla tyrosine levels, however, remained at fasting. Infusion of I.-alanyl-L-tyrosine at 2 mmole/kg/day increased plasnia tyrosine above fasting levels and maintained tissue tyrosine at levels seen in orally fed control animals without increasing the percent lost in urine (5.5'10). Rapid utilization of L-alanyl-L-tyrosine was noted at both infusion levels with no accumulation of peptide noted in plasma. Plasma and tissue free tyrosine pools were rapidly labeled, as was tissue protein. Radioactivity incorporated in tissue protein was shown to be tyrosine after acid hyrolysis.
Summary
Tyrosine peptides, such as L-alanyl-L-tyrosine, have excellent solubility and are potential sources of iv tyrosine. Infusion of Lalanyl-1.-U-'T-tyrosine as part of a total parenteral nutrition reginien in the rat at a level of 0.5 mmole/kg/day resulted in rapid labeling of tissue tyrosine pools, production of I4CO2, incorporation of 14C-labeled tyrosine into protein, and minimal urinary losses (7.7%). Plasnla tyrosine levels, however, remained at fasting. Infusion of I.-alanyl-L-tyrosine at 2 mmole/kg/day increased plasnia tyrosine above fasting levels and maintained tissue tyrosine at levels seen in orally fed control animals without increasing the percent lost in urine (5.5'10). Rapid utilization of L-alanyl-L-tyrosine was noted at both infusion levels with no accumulation of peptide noted in plasma. Plasma and tissue free tyrosine pools were rapidly labeled, as was tissue protein. Radioactivity incorporated in tissue protein was shown to be tyrosine after acid hyrolysis.
Speculation
Tyrosine content of parenteral solutions is limited by poor tyrosine solubility. Tyrosine peptides are soluble and are well utilized during iv feeding of adult rats. This suggests that tyrosine peptides are a reasonable source for supplying the tyrosine requirements of iv fed infants.
Cystine and tyrosine are essential amino acids for some premature infants (19, 33, 41) . Both amino acids have limited solubility, and cannot be added to total parenteral nutrition solutions in quantities sufficient to meet the infants requirements. The absence of these amino acids results in depresed cystine and tyrosine levels in infants infused with such solutions (30, 35, 38) .
Soluble peptides of cystine and tyrosine are potential sources for adding these amino acids to parenteral solutions (36) . Although some studies suggested that peptide nitrogen is not well utilized during parenteral nutrition (7-1 1, 13, 16, 21, 23). peptide utilization is nearly equal to that of infused amino acids once products of the Maillard reaction are eliminated from the parenteral solutions (I I. 36, 39) . Preliminary studies (36) indicated good utilization of L-alanyl-I.-tyrosine as a tyrosine source in adult rats when administered at 0.5 mmole/kg/day either by ip injection or as part of a total parenteral nutrition regimen. The peptide was utilized as a tyrosine source for protein synthesis, as evidenced by incorporation of tyrosine into tissue protein, and for energy production, as evidenced by rapid conversion to carbon dioxide. However, plasma tyrosine levels remained in the fasting range and 7.7% of peptide tyrosine was lost in the urine. The present study compares infusion of I--alanyl-L-tyrosine at 0.5 and 2.0 mmole/kg/day as part of a parenteral nutrition regimen in adult rats to determine whether: I) good utilization occurs at higher peptide infusion levels; 2) plasma tyrosine levels can be increased above fasting levels; and 3) urinary losses of tyrosine will increase at higher infusion levels.
MATERIALS AND METIIODS
I.-Alanyl-L-tyrosine and L-alanyl-L-U-14C-tyrosine were purchased from Vega-Fox Biochemicals, Tucson, Az. The purity was confirmed by amino acid analysis before and after acid hydrolysis.
Healthy male Sprague-Dawley rats, weighing 400-500 g were used for all experiments. The method of Popovic and Popovic (3 1) was used for the cannulation of the animals. This method allows work on unanaesthetized animals and simultaneous sampling of arterial blood while the nutrient solution is infused into the venous circulation. The catheters were placed under ether anesthesia, and the animals allowed to recover from the operative procedure for a 2-day period.
After recovery, the animals were placed in restraining metabolism cages and alimented parenterally using the parenteral nutrition solution described by Steiger et a1 (40) for a 24-hr period. The base solution was by adding sterile 50% dextrose solution to an 8.5% solution of crystalline amino acids (FreAmine, McGaw Laboratories, Glendale, CA) 2:1, to yield the 33% glucose-2.8% amino acid solution infused. This solution does not contain tyrosine. Electrolytes and vitamins were added to the recommendation of Steiger et al. (40) . The solution was infused into the venous cannula at a rate of 50-55 ml/day by pump (Extra-corporal Medical Specialties, Bridgeport, PA). Total daily energy intake was between 73 to 80 kcal, sufficient to provide maintenance requirements of adult rats (40, 44) .
Four groups of five animals each were studied. The first group was infused with the parenteral solution without added peptide. The second and third groups of animals were infused with the same parenteral alimentation solution to which I.-alanyl-L-tyrosine was added at levels providing either 0.5 or 2.0 mmoles of peptide/ kg body wt/24 hr infusion. Sufficient L-alanyl-L-U-'4C-tyrosine was added so that 15 pCi was infused per 24 hr in each case. The fourth group of rats was fed with standard rat chow after catheter placement. The infused solutions were sterilized by passage through a 0.22 p membrane filter (Millipore Corporation, Bedford, MA) before infusion.
Sequential 4-hr urine samples were collected in iced graduate cylinders during the infusion, and deproteinized immediately with sulfosalicylic acid (15). Blood samples (0.5 ml) were drawn from the arterial cannula at 0,6, and 24 hr, he~arinized, and centrifuged u to separate plasma and erythrocytes. Plasma was immediately deoroteinized bv addition of an eaual volume of 8% sulfosalicvlic acid. The precipitated protein was removed by centrifugation (Airfuge, Beckman Instruments, Palo Alto, CA). Erythrocytes were prepared for amino acid analysis, after removal of the white cell layer, by hemolyzing one volume of packed cells with three volumes of cold thiodiglycol solution (0.5% v/v), and then deproteinized by the addition of an equal volume of 8% sulfosalicylic acid. The precipitated protein was removed by centrifugation. All physiologic fluid samples were either analyzed immediately, or stored at -70' C until analysis to prevent loss of glutamine and cystine (14, 29).
Amino acid analyses were carried out using Beckman 121M amino acid analyzers (Beckman Instruments, Palo Alto, CA). labeled carbon dioxide collected as described by Palese and Simultaneous radioactivity-amino acid analyses were carried out Tephly (27) . as described by Stegink (37) . Statistical analysis of the data was carried out using the paired At the end of the parenteral infusion, the animals were lightly t test and the Student's c test (34) . anesthetized with ether, and the tissue samples (liver, kidney. muscle, intestine, brain, stomach, heart, lung, spleen) quickly excised, blotted, and weighed. The remaining carcass was skinned. One g portions of each tissue were homogenized in 10 ml of 5% sulfosalicylic acid for 3 min in a Virtis microhomogenizer. The precipitated protein was removed by centrifugation at 20,000 x g for 15 min at 4' C in a refrigerated centrifuge (International B-20), and aliquotes for the supernatant solution were assayed for radioactivity and amino acid distribution as described by Stegink (37) . The entire skin and remaining carcass were similarly treated.
The total radioactivity present in plasma, urine, tissue, and carcass homogenates was determined by adding aliquots of the homogenate to 10 ml of scintillation fluid (6). The values were quench corrected. Background noise was eliminated by counting an appropriate portion of control urine, plasma, or tissue homogenates. The quantity of radioactivity present in protein fractions of the samples was determined by dissolving a specific weight of precipitated protein in hyamine hydroxide (Packard Instrument Co., Downers Grove, IL) followed by digestion for 4 8 hr at 37O C before counting.
The d i~t r i b~t i o n of radioactivity between the various amino acids in the protein fraction was determined after acid hydrolysis. The precipitated protein was collected by centrifugation, suspended in 5 ml of 3.5% sulfosalicylic acid, and the protein again collected by centrifugation. The supernatant solution was discarded and the procedure repeated three times to remove any traces of free tyrosine or alanyl-tyrosine. The precipitated protein was then dissolved in 6 N HCI in a hydrolysis tube. The tube was evacuated using a vacuum pump and then flushed with dry, oxygen-free nitrogen gas. After repeating the process three times, the tube was sealed and the protein hydrolyzed for 22 hr at 115O C. The hydrolysate was lyophilized to dryness, the residue dissolved in 5% sulfosalicylic acid, and then subjected to the simultaneous radioactivity-amino acid analysis procedure (37) . In those animals studied for the rate of carbon dioxide production, the animals were placed in a glass metabolism chamber, and the RESULTS Plasma amino acid levels, both before parenteral alimentation and after 24 hr infusion, are shown in Table 1 . In general, plasma levels of those amino acids present in the parenteral solution increased from the fasting levels noted in preinfusion samples, to levels considered postprandial in samples taken after 24 hr infusion. Plasma levels of those amino acids not present in the parenteral solution remained at fasting levels or decreased. The addition of I.-alanyl-L-tyrosine to the parenteral solution at a level of 0.5 mmole/kg/day did not affect plasma tyrosine levels, which remained at preinfusion values, and were similar to those noted in rats infused with the tyrosine-free parenteral solution without added peptide. Animals infused with I.-alanyl-I.-tyrosine at 2 mmole/kg/day had increased plasma tyrosine levels. Plasma tyrosine reached 9.2 + 2.1 pmoles/dl (mean + SD) 6 hr into the infusion, stabilized by 24 hr at 13.0 f 2.13 pmoles/dl, and did not increase further after 4 8 hr infusion at this level.
Plasma alanine levels in animals infused with I.-alanyl-I.-tyrosine at 0.5 mmole/kg/day were similar to those noted in animals infused without peptide, but were significantly higher ( P = 0.001) in animals infused with I.-alanyl-L-tyrosine at 2 mmole/kg/day.
The infusion of radioactivity-labeled peptide (I.-alanyl-I.-U-"Ctyrosine) made it possible to evaluate utilization of the peptide bound tyrosine for both energy production ( C 0 2 ) and protein synthesis. The data in Table 2 demonstrate peptide utilization during total parenteral alimentation at both infusion levels. The distribution of infused label among body tissues and fluids was similar at both infusion levels, although animals infused at 2 mmole/kg oxidized a greater percent of the infused tyrosine, and incorporated a smaller percent into the tissue protein than animals infused at 0.5 mmole/kg.
Muscle, liver, plasma, intestine, and kidney accumulated substantial amounts of radioactivity at both infusion levels. Determination of the radioactivity distribution between the free amino acid fraction, protein bound fraction, and free alanyl-tyrosine of the various tissue fractions, showed 10-20% of the radioactivity present as free tyrosine, with the remainder in protein-bound form. Only trace quantities of radioactivity were detected at the I.-alanyl-I.-tyrosine position. The protein fraction from the various tissues contained 80-90% of the total activity. Isolation of tissue or plasma protein, followed by acid hydrolysis, and analysis for distribution of radioactivity among the various amino acids, demonstrated that 94-99% of the radioactivity present in the protein was tyrosine. These data demonstrate incorporation of labeled tyrosine into protein. Labeling did not result from conversion of tyrosine into nonessential amino acids with subsequent incorporation into protein.
Relatively little radioactivity was lost in the urine, and the percent of infused label appearing in the urine was similar at both peptide infusion levels. Animals infused at 0.5 mmole/kg/day excreted 7.7% of the label in the urine, (74% was tyrosine and 26% alanyl-tyrosine). Animals infused at 2 mmoles/kg/day excreted 5.4% of the label infused in the urine; 55% of the label appearing as tyrosine and 45% of the label eluting as alanyl-tyrosine (47) .
Urinary tyrosine and alanine excretion were significantly higher (P = 0.00 1) in animals infused with parenteral solutions containing I.-alanyl-L-tyrosine than in animals infused without peptide (Table   3) . Animals infused at 0.5 mmole/kg/day received a mean of 225 pmoles of peptide bound tyrosine and alanine dajly. Urinary tyrosine excretion in these animals increased 10.3 pmole/day, and alanine excretion 9.4 pmole/day above levels noted in control animals infused without peptide. This increase in tyrosine excretion occurred despite tyrosine levels which were unchanged from fasting levels (Table I ) and which were identical to those observed in control animals. Animals infused with I.-alanyl-I--tyrosine at 2 mmole/kg/day received a mean of 800 pmoles of peptide bound tyrosine and alanine daily. Urinary tyrosine excretion in these animals increased by 20 pmole/day and alanine levels increased 23 pmole/day above levels noted in control animals infused without peptide.
The data in Table 4 show the effect of the parenteral feeding regimens upon erythrocyte free amino acid levels. Changes in erythrocyte levels of free amino acids during the infusion periods were similar to those observed in plasma (Table I) . Erythrocyte alanine and tyrosine levels were significantly higher in animals infused with the solution providing alanyl-tyrosine at 2 mmolel kg/day than in animals infused with the tyrosine-free solution, indicating utilization of the peptide to supply erythrocyte tyrosine pools.
The data in Table 5 suggest that infusion of alanyl-tyrosine at 2.0 mmole/kg/day helps maintain tyrosine levels in certain tissues at values seen in orally fed control animals, in contrast to animals fed parenterally without a tyrosine source. Liver and kidney tyrosine levels were lower in parenterally fed animals receiving either the tyrosine-free base solution, or the base solution containing 0.5 mmoles peptide/kg/day than in orally fed control animals. Liver and kidney tyrosine levels in animals infused with 2.0 mmoles peptide/kg/day were similar to those seen in orally fed control animals. Tissue alanine levels showed few differences between experimental groups, although liver alanine levels were significantly higher in animals infused with alanyl-tyrosine at 2.0 mmole/kg/day.
These data indicate good utilization of alanyl-tyrosine as a parenteral tyrosine source for protein synthesis and suggest that the infusion of adequate alanyl-tyrosine maintains plasma, erythrocyte, and tissue tyrosine pools in parenterally fed animals.
DISCUSSION
The evidence for metabolic utilization of tyrosine when administered as alanyl-tyrosine is strong and consists of three elements.
First, 40-50% of the radioactivity administered appears as 'vcarbon dioxide, when peptide was administered as part of the parenteral regimen at either 0.5 or 2.0 mmole/kg/day. This clearly indicates hydrolysis of the peptide and oxidation of the tyrosine. Second, the increased plasma and tissue tyrosine levels daring infusion at 2.0 mmole/kg/day, and the presence of radioactivity as tyrosine in the free amino acid pools of both plasma and tissues indicates its availability. Finally, and most importantly, from the perspective of growth and tissue repair, radioactive tyrosine was incorporated into both plasma and tissue proteins as tyrosine, and protein-bound tyrosine accounted for 80-90% of the radioactivity found in these tissues. The data demonstrate that tyrosine from alanyl-tyrosine is rapidly metabolized when administered as part of a parenteral alimentation solution and provides free tyrosine for energy substrate, tissue tyrosine pools, and protein synthesis. Urinary losses are small (5-8%). These results indicate L-alanyl-Ltyrosine serves as a tyrosine source for the rat during iv feeding.
Snyderman (33) has presented evidence that tyrosine is an essential amino acid for some premature infants even in the presence of adequate phenylalanine intake. She has estimated the tyrosine requirements for such orally fed infants to be 50-120 mg/ kg/day (32, 33). Extrapolation of her oral feeding data to parenteral alimentation suggests the need for 50-120 mg (0.3-0.66 'Amino acids present in parenteral solution. mmole) of tyrosine per 100 ml of solution, assuming a n infusion rate of 100-120 ml/kg/24 h r o f a standard parenteral solution o f 2.5% amino acids-2570 glucose. Alanyl-tyrosine has a solubility of approximately 22 mmole/100 m1 (36) . This solubility may permit development of the peptide as a n additive for iv solutions in a manner similar to that currently used for electrolytes. This would eliminate the need for its presence in the amino acid mixture fed all infants.
Some studies have suggested that peptides, such as those found in protein hydrolysate solutions, are not well utilized during iv infusion (7-1 1, 13, 16, 21, 23). However, peptide fractions of protein hydrolysates are well utilized during iv administration in infants a n d adults in Maillard condensation products are excluded from the solution ( 1 1. 36, 39) . T h e present data support that hypothesis, show good utilization of infused peptide, a n d agree with data o f Adibi a n d colleagues (2. 3) who reported rapid metabolism o f single doses of glycyl-glycine a n d glycyl-leucine injected into the jugular vein of rats. Although these studies with I.-alanyl-I,-tyrosine are restricted to adult animals, the authors believe that the neonate will also utilize the peptide. H u m a n infants metabolize peptides present in protein hydrolysates administered parenterally (36, 39) .
With the exception of tyrosine a n d alanine, plasma levels of amino acids were similar in all groups o f parenterally fed rats after 24 h r infusion. Plasma levels o f those amino acids present in free form in the parenteral solution increased from fasting levels to those considered postprandial, while levels o f those amino acids not present were generally unchanged o r decreased. Plasma ala-
